Ashkan Safavi

Ashkan Safavi

Auto-generated profile, based on publicly available information

Ashkan Safavi

Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2020 in Vaccine
Verified
Journal Article
Closed access
ASAshkan Safavi
Ashkan Safavi
AKAmirhosein Kefayat
Amirhosein Kefayat
EMElham Mahdevar
Elham Mahdevar
AAArdavan Abiri
Ardavan Abiri
FGFatemeh Ghahremani
Fatemeh Ghahremani

18 February 2021 in Journal of Biomolecular Structure and Dynamics
Verified
Journal Article
Closed access
EMElham Mahdevar
Elham Mahdevar
ASAshkan Safavi
Ashkan Safavi
AAArdavan Abiri
Ardavan Abiri
AKAmirhosein Kefayat
Amirhosein Kefayat
SHSeyed Hossein Hejazi
Seyed Hossein Hejazi
VIVahid Iranpur
Vahid Iranpur
Recently, cancer immunotherapy has gained lots of attention to replace the current chemoradiation approaches and multi-epitope cancer vaccines are manifesting as the next generation of cancer immunotherapy. Therefore, in this study, we used multiple immunoinformatics approaches along with other computational approaches to design a novel multi-epitope vaccine against breast cancer. The most immunogenic regions of the BORIS cancer-testis antigen were selected according to the binding affinity to MHC-I and II molecules as well as containing multiple cytotoxic T lymphocyte (CTL) epitopes by multiple immunoinformatics servers. The selected regions were linked together by GPGPG linker. Also, a T helper epitope (PADRE) and the TLR-4/MD-2 agonist (L7/L12 ribosomal protein from mycobacterium) were incorporated by A(EAAAK)3A linker to form the final vaccine construct. Then, its physicochemical properties, cleavage sites, TAP transport efficiency, B cell epitopes, IFN-γ inducing epitopes and population coverage were predicted. The final vaccine construct was reverse translated, codon-optimized and inserted into pcDNA3.1 to form the DNA vaccine. The final vaccine construct was a stable, immunogenic and non-allergenic protein that contained numerous CTL epitopes, IFN-γ inducing epitopes and several linear and conformational B cell epitopes. Also, the final vaccine construct formed stable and significant interactions with TLR-4/MD-2 complex according to molecular docking and dynamics simulations. Moreover, its world population coverage for HLA-I and HLA-II were about 93% and 96%, respectively. Taking together, these preliminary results can be used as an appropriate platform for further experimental investigations. Communicated by Ramaswamy H. Sarma

16 December 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
AKAmirhosein Kefayat
Amirhosein Kefayat
FGFatemeh Ghahremani
Fatemeh Ghahremani
ASAshkan Safavi
Ashkan Safavi
AHAlireza Hajiaghababa
Alireza Hajiaghababa
JMJamal Moshtaghian
Jamal Moshtaghian
Different chemical and nanomaterial agents have been introduced for radiosensitizing purposes. However, many researchers believe these agents are far away from clinical application due to side effects and limited knowledge about their behavior in the human body. In this study, C-phycocyanin (C-PC) was used as a natural radiosensitizer for enhancement of radiation therapy (RT) efficacy. C-PC treatment’s effect on the COX-2 expression of cancer cells was investigated by flow cytometry, western blot, qRT-PCR analyses in vitro and in vivo. Subsequently, the radiosensitizing effect of C-PC treatment was investigated by MTT and clonogenic cell survival assays for CT-26, DLD-1, HT-29 colon cancer cell lines and the CRL-1831 as normal colonic cells. In addition, the C-PC treatment effect on the radiation therapy efficacy was evaluated according to CT-26 tumor’s growth progression and immunohistochemistry analyses of Ki-67 labeling index. C-PC treatment (200 µg/mL) could significantly enhance the radiation therapy efficacy in vitro and in vivo. Synergistic interaction was detected at C-PC and radiation beams co-treatment based on Chou and Talalay formula (combination index <1), especially at 200 µg/mL C-PC and 6 Gy radiation dosages. The acquired DEF of C-PC treatment was 1.39, 1.4, 1.63, and 1.05 for CT-26, DLD-1, HT-29, and CRL-1831 cells, respectively. Also, C-PC + RT treated mice exhibited 35.2% lower mean tumors’ volume and about 6 days more survival time in comparison with the RT group (P < 0.05). In addition, C-PC + RT group exhibited 54% lower Ki-67 index in comparison with the RT group. Therefore, C-PC can exhibit high radiosensitizing effects. However, the potential cardiovascular risks of C-PC as a COX-2 inhibitor should be evaluated with extensive preclinical testing before developing this agent for clinical trials.

4 June 2020 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Closed access
ASAshkan Safavi
Ashkan Safavi
AKAmirhosein Kefayat
Amirhosein Kefayat
EMElham Mahdevar
Elham Mahdevar
FGFatemeh Ghahremani
Fatemeh Ghahremani
NNNavid Nezafat
Navid Nezafat
MMMohammad Hossein Modarressi
Mohammad Hossein Modarressi
Multiepitope cancer vaccines have gained lots of attention for prophylactic and therapeutic purposes in cancer patients. In our previous study, multiepitope DNA and peptide cancer vaccines consisted of the most immunodominant epitopes of ACRBP and SYCP1 antigens were designed by bioinformatic tools. In this study, the effect of prophylactic co-immunization with these DNA and peptide cancer vaccines in the 4T1 breast cancer animal model was assessed. Serum levels of the peptide-specific IgG total, IgG2a and IgG1 were measured by enzyme-linked immunosorbent assay (ELISA). Also, the efficacy of the immunized mice splenocytes’ for producing interleukin-4 (IL-4) and interferon-γ (IFN-γ) was evaluated. The co-immunization caused a significant (P < .05) increase in the serum levels of IgG1 and IgG2a. The co-immunized mice splenocytes exhibited significantly enhanced IL-4 (6.6-fold) and IFN-γ (19-fold) production. Also, their lymphocytes exhibited higher proliferation rate (3-fold) and granzyme B production (6.5-fold) in comparison with the control. The prophylactic co-immunization significantly decreased the breast tumors’ volume (78%) and increased the tumor-bearing mice survival time (37.5%) in comparison with the control. Taking together, prophylactic co-immunization with these multiepitope DNA and peptide cancer vaccines can activate the immune system against breast cancer. However, further experiments are needed to evaluate their efficacy from different angles.

5 November 2019 in Phytotherapy Research
Verified
Journal Article
Closed access
PDF file
AKAmirhosein Kefayat
Amirhosein Kefayat
FGFatemeh Ghahremani
Fatemeh Ghahremani
ASAshkan Safavi
Ashkan Safavi
AHAlireza Hajiaghababa
Alireza Hajiaghababa
JMJamal Moshtaghian
Jamal Moshtaghian